P-139: Performance of a NEXT-generation algorithm for a tubeless automated insulin delivery system in children with type 1 diabetes: findings from the STRIVE randomized trial
P-139: Leistung eines NEXT-Generation-Algorithmus für ein schlauchloses automatisiertes Insulinabgabesystem bei Kindern mit Typ-1-Diabetes: Ergebnisse der STRIVE-Randomisierungsstudie
Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)
DOI: 10.1159/hrp/adaag020.198 ↗Auf einen Blick
Bei Kindern mit Typ-1-Diabetes war der NEXT-Generation-Algorithmus von Omnipod 6 sicher und zeigte eine starke Wirksamkeit. In der älteren Gruppe nahm die Zeit im engen Zielbereich zu; schwere Hypoglykämien oder DKA traten nicht auf.
Fragestellung
Wie sicher und wirksam ist der NEXT-Generation-Algorithmus von Omnipod 6 bei Kindern mit Typ-1-Diabetes im Vergleich zu Omnipod 5?
Methode
Multizentrische, randomisierte Crossover-Studie; Omnipod 6 mit Ziel 100 mg/dL vs. Omnipod 5 mit Ziel 110 mg/dL je 4 Wochen, danach 4 Wochen restriktive Bolusphase.
Ergebnisse
2 Altersgruppen: 2-<6 Jahre (n=29) und 6-<14 Jahre (n=36). Zeit im engen Bereich 70-140 mg/dL stieg bei 6-<14 Jahren um 5,5 % (+1,3 h/Tag); <54 und <70 mg/dL blieben niedrig. In der restriktiven Bolusphase stiegen TIR/TITR weiter.
Schlussfolgerung der Autor:innen
Die Ergebnisse zeigen Sicherheit und ein starkes Wirksamkeitspotenzial des NEXT-Generation-Omnipod-6-Algorithmus bei Kindern mit Typ-1-Diabetes ab 2 Jahren.
Kernaussagen
- Zeit im engen Bereich stieg bei 6-<14 Jahren um 5,5 % (+1,3 h/Tag)
- <54 und <70 mg/dL blieben in beiden Gruppen niedrig
- Keine schweren Hypoglykämien oder DKA-Ereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von G Forlenza und 10 weiteren Autor:innen.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
A recent randomized crossover trial compared a next-generation algorithm for Omnipod (Omnipod 6) with the first-generation Omnipod® 5 Automated Insulin Delivery System in a diverse population including adults (T1D/T2D) and children (T1D).
Objectives
This subgroup analysis assessed safety and efficacy within the vulnerable population of children with T1D who face elevated hypoglycemia risk.
Methods
This multicenter, randomized, crossover study compared Omnipod 6 at a 100mg/dL (5.6mmol/L) target with Omnipod 5 at a 110mg/dL (6.1mmol/L) target (4 weeks each) in current Omnipod 5 users. Users continued use of Omnipod 6 for an additional 4 weeks in a restricted bolus phase (goal of ≤3 boluses/day). Safety and efficacy outcomes were evaluated in children ages 2-<6 and 6-<14y.
Results
Children aged 2-<6y (n=29; age: 4±1y, baseline A1C: 7.0±0.8%) and 6-<14y (n=36; age: 11±2y, baseline A1C: 7.0±0.8%) with T1D were randomly assigned. The 100mg/dL target was used 82% and 95% of time in the 2-<6y and 6-<14y groups, respectively, with Omnipod 6. Time in tight range (70-140mg/dL) increased by 5.5% (+1.3h/d) with Omnipod 6 in those aged 6-<14y with no significant change in those aged 2-<6y. Time <54 and <70mg/dL remained low in both groups, meeting the non-inferiority margins of 0.75% and 3%, respectively (Table). A total of 63 children entered and completed the restricted bolus phase. TIR and TITR remained high with less boluses per day and algorithm insulin delivery increasing by a mean treatment group difference of 6% (4%, 8%) and 5% (2%, 7%), both p<0.001, vs. the Omnipod 6 phase in children 2-<6y and 6-<14y, respectively. No severe hypoglycemia or DKA events occurred.
Conclusions
These results demonstrate safety and strong efficacy potential of the next-generation Omnipod 6 algorithm in children with T1D as young as 2y.
Zitieren
APA
Forlenza, G., DeSalvo, D., Laffel, L., Criego, A., Castorino, K., MacLeish, S., Raghinaru, D., Beck, R., Ly, T., Sherr, J., & Consortium, S. (2026). P-139: Performance of a NEXT-generation algorithm for a tubeless automated insulin delivery system in children with type 1 diabetes: findings from the STRIVE randomized trial. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.198
Vancouver
Forlenza G, DeSalvo D, Laffel L, Criego A, Castorino K, MacLeish S, et al. P-139: Performance of a NEXT-generation algorithm for a tubeless automated insulin delivery system in children with type 1 diabetes: findings from the STRIVE randomized trial. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.198
BibTeX
@article{Forlenza2026,
author = {Forlenza, G and DeSalvo, D and Laffel, L and Criego, A and Castorino, K and MacLeish, S and Raghinaru, D and Beck, R and Ly, T and Sherr, J and Consortium, STRIVE},
title = {P-139: Performance of a NEXT-generation algorithm for a tubeless automated insulin delivery system in children with type 1 diabetes: findings from the STRIVE randomized trial},
journal = {Hormone Research in Paediatrics},
year = {2026},
volume = {99},
number = {Supplement_4},
doi = {10.1159/hrp/adaag020.198}
}
EUVIMED